Antoine Dipsia, MD
Adult Medicine · W. Sacramento, CANPI 1013093558
Payments from drug & device makers
Across 529 payments — averaging $39.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Boehringer Ingelheim$2K
- Lilly USA, LLC$2K
- Bayer$2K
- AstraZeneca$2K
- GSK$1K
- plus $9K from 32 others
What the payments were for
- Food & beverage$20,761100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 104 | $3,095 |
| Boehringer Ingelheim | 57 | $1,990 |
| Lilly USA, LLC | 63 | $1,958 |
| Bayer | 55 | $1,947 |
| AstraZeneca | 26 | $1,762 |
| GSK | 27 | $1,264 |
| Amgen | 17 | $917 |
| Johnson & Johnson | 12 | $888 |
| AbbVie | 27 | $665 |
| Merck | 25 | $658 |
| Sanofi | 7 | $637 |
| Regeneron Healthcare Solutions, Inc. | 5 | $592 |
| Idorsia Pharmaceuticals US Inc | 6 | $525 |
| Biohaven Pharmaceuticals, Inc. | 11 | $520 |
| Novartis | 10 | $471 |
| Pfizer | 6 | $404 |
| Aimmune Therapeutics, Inc. | 4 | $318 |
| Dexcom, Inc. | 9 | $267 |
| Verona Pharma, Inc. | 2 | $226 |
| Scilex Pharmaceuticals Inc. | 12 | $217 |
| Redhill Biopharma Inc. | 6 | $208 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $197 |
| E.r. Squibb & Sons, L.L.C. | 11 | $182 |
| Amarin Pharma, Inc. | 2 | $136 |
| Corcept Therapeutics | 1 | $123 |
| Gilead | 1 | $113 |
| Kowa Pharmaceuticals America, Inc. | 1 | $109 |
| Radius Health, Inc. | 1 | $104 |
| Abbott | 4 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $73 |
| Electromed, Inc. | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Averitas Pharma Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Circassia Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Strongbridge US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,794 in reported general payments places this provider in the 95th percentile of 221 adult medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 140 | $169,668 |
| OzempicSemaglutide | 108 | $153,414 |
| KerendiaFinerenone | 45 | $71,543 |
| FarxigaDapagliflozin Propanediol | 38 | $47,405 |
| MounjaroTirzepatide | 19 | $24,530 |
| EliquisApixaban | 15 | $22,043 |
| Spiriva RespimatTiotropium Bromide | 24 | $16,352 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,515 |
| Varenicline Tartrate | 18 | $3,657 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $2,952 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,125 |
| Lidocaine | 11 | $1,819 |
| Diclofenac Sodium | 48 | $1,684 |
| Atorvastatin Calcium | 244 | $1,535 |
| Gabapentin | 95 | $1,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $1,990 | $186,020164 claims |
| Novo NordiskOzempic | $3,095 | $153,414108 claims |
| BayerKerendia | $1,947 | $71,54345 claims |
| AstraZenecaFarxiga | $1,762 | $47,40538 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $1,958 | $25,00431 claims |
| PfizerEliquis | $404 | $22,04315 claims |
| GSKBreo Ellipta | $1,264 | $6,51514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 221 adult medicine providers in California.
Other adult medicine in W. Sacramento
- Gary BooneSan Diego$4.9M
- Salil NadkarniWest Hollywood$3.3M
- Robert FerreraSacramento$2.6M
- Ramin FarsadEncinitas$2.2M
- Susan HutchinsonLaguna Hills$1M
- Natalia GuzmanLos Angeles$583K
- Yasuko KidokoroSan Diego$267K
- Richard FauselRancho Mirage$30K
- Benedicto EstoestaValley Springs$22K
- Patrick WelchArroyo Grande$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.